8-KEarnings & ResultsOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Financial Results (Nov 4, 2021)

Filed November 4, 2021For Securities:ONCBEIGF

Summary

BeiGene, Ltd. (ONC) filed an 8-K on November 4, 2021, to report its financial results for the third quarter and first nine months of 2021. While the filing itself is brief, it references a press release containing detailed financial information and operational updates. Investors should refer to the full press release (Exhibit 99.1) for specifics on revenue, expenses, net loss, and cash flow. In addition to financial performance, the 8-K highlights significant clinical progress, particularly in the hematology division. The company announced upcoming presentations of clinical and real-world data for its BRUKINSA® (zanubrutinib) program at the 63rd American Society of Hematology (ASH) Annual Meeting. This includes crucial Phase 3 SEQUOIA trial data comparing BRUKINSA® to a standard treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), a key development for the company's oncology pipeline.

Key Highlights

  • 1BeiGene reported financial results for the third quarter and nine months ended September 30, 2021.
  • 2The company will present clinical results and real-world data for its hematology program at the 63rd ASH Annual Meeting (December 11-14, 2021).
  • 3Key presentations will include Phase 3 SEQUOIA trial data for BRUKINSA® (zanubrutinib) in treatment-naïve Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL).
  • 4The SEQUOIA trial compares BRUKINSA® against the combination of bendamustine and rituximab (B+R).
  • 5The ASH meeting will be conducted in a hybrid format (in-person in Atlanta, GA, and virtually).
  • 6The filing incorporates by reference two press releases containing detailed financial results and business updates.

Frequently Asked Questions

The 8-K filing references a press release (Exhibit 99.1) that contains BeiGene's financial results for the three and nine months ended September 30, 2021. Investors should consult this press release for specific details on revenue, net loss, and other financial metrics.

BeiGene is presenting important clinical data on its hematology program, particularly for BRUKINSA® (zanubrutinib), at the 63rd ASH Annual Meeting. This includes data from the Phase 3 SEQUOIA trial, which is a critical study for the drug's potential in treating Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).

In the Phase 3 SEQUOIA trial for treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), BRUKINSA® is being compared to the standard-of-care combination of bendamustine and rituximab (B+R).

The detailed information is available in two press releases attached as exhibits to this Form 8-K: Exhibit 99.1 for the Q3 2021 financial results and Exhibit 99.2 for the clinical data presentation announcements at ASH.